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Abstract: Aims Hybrid imaging provides a non-invasive assessment of coronary anatomy and
myocardial perfusion. We sought to evaluate the added clinical value of hybrid imaging
in a multi-centre multi-vendor setting.
Methods and results Fourteen centres enrolled 252 patients with stable angina and
intermediate (20-90%) pre-test likelihood of coronary artery disease (CAD) who
underwent myocardial perfusion scintigraphy (MPS), CT coronary angiography
(CTCA), and quantitative coronary angiography (QCA) with fractional flow reserve
(FFR). Hybrid MPS/CTCA images were obtained by 3D image fusion. Blinded core-lab
analyses were performed for CTCA, MPS, QCA and hybrid datasets. Hemodynamically
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
significant CAD was ruled-in non-invasively in the presence of a matched finding
(myocardial perfusion defect co-localized with stenosed coronary artery) and ruled-out
with normal findings (both CTCA and MPS normal).
Overall prevalence of significant CAD on QCA (>70% stenosis or 30-70% with
FFR≤0.80) was 37%. Of 1004 pathological myocardial segments on MPS, 246 (25%)
were reclassified from their standard coronary distribution to another territory by hybrid
imaging. In this respect, in 45/252 (18%) patients, hybrid imaging reassigned an entire
perfusion defect to another coronary territory, changing the final diagnosis in 42% of
the cases. Hybrid imaging allowed non-invasive CAD rule-out in 41%, and rule-in in
24% of patients, with a negative and positive predictive value of 88% and 87%,
respectively.
Conclusions In patients at intermediate risk of CAD, hybrid imaging allows non-invasive
co-localization of myocardial perfusion defects and subtending coronary arteries,
impacting clinical decision-making in almost one every five subjects.
Response to Reviewers: Please see separate extensive rebuttal letter appended to the submitted manuscript
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Reply to reviewers’ comments: 
 
We are thankful to all of the reviewers for taking the time of a thoughtful and detailed review of 
our manucript. We are convinced that their comments have significantly contributed to improve 
the quality of the manuscript. Please find enclosed a point-by-point reply to the reviewers’ 
comments. Changes within the manuscript are highlighted in red.  
 
 
Reviewer #1: 
 
1.  
Reviewer: Indeed, hybrid- multi-modality imaging showed a great promise to show "more" than 
the individual modalities are able to do. I fully agree with the authors that a multi-center, multi-
vendor setting is mandatory to evaluate these new technologies onto their possible clinical 
impact. Further evaluation using standardized operating procedures (SOP) is also very 
important to be able to compare the results at a high quality. 
Having said this, and perhaps I overlooked it, if you compare the results of the core-lab to those 
generated by the individual centers themselves, is there a difference? In other words, I assume 
that every center will ultimately perform their own analysis? Can you elaborate on this? I 
assume that you do not use (need) the core-lab for daily clinical practice? 
Authors: Many thanks for this thoughtful comment and the possibility to clarify this issue. 
Indeed, to improve the quality and generalizability of our findings, the trial was fully conducted 
with core-lab data (i.e. with individual and independent core labs for CT, SPECT, PET, and hybrid 
imaging). This was an attempt to avoid any center-bias. However, as highlighted by the recently 
published main EVINCI trial (Neglia D et al. Circ Cardiovasc Imaging. 2015 Mar;8(3). pii: 
e002179. doi: 10.1161/CIRCIMAGING.114.002179), there are significant differences between 
individual center- and core lab-analyses. Therefore, and following the suggestion of this 
reviewer, we have added a separate accuracy analysis with the individual center analysis in the 
supplementary material section (Suppl figure 1) of the revised manuscript, and the results are 
discussed on page 13 of the revised manuscript: Notably, on centre-based analysis the diagnostic 
accuracy of the different non-invasive imaging modalities was generally improved compared to 
the core-lab data. Nevertheless, even when only individual centre-data were considered, hybrid 
imaging maintained significantly elevated specificity and overall diagnostic accuracy, both at 
per-patient and vessel-based analysis.  
 
2.  
Reviewer: Speaking about the analysis at the core-lab, on page 5 you write that analysis was 
performed by an in-house developed software (PMOD 3.6, PMOD Technologies Ltd., Zurich, 
Switzerland). However, I am used to identification of  "in-house" when the software (or product) 
is made in the institution that writes the publication. Now it is related to a commercial company, 
so I am a bit confused with the term of "in-house". 
Authors: Many thanks for pointing this out. The PMod  Software was developed in-house but is 
now commercially available. We have therefore changed the sentence acocording to this 
reviewers suggestion: „In case of H215O-PET images, parametric myocardial blood flow datasets, 
showing flows on a segmental level, were generated based on quantitative analysis performed 
using a commercially available software, (PMOD 3.6 software package. PMOD Technologies Ltd., 
Zurich, Switzerland).“ 
 
3.  
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Reviewer: The methodology to apply hybrid imaging is expensive and it also needs radiation. It is 
perhaps outside the scope of your paper, but do you think that your results could be used to 
justify the proposed method to evaluate the patients as in your cohort on a larger scale and 
make it standard clinical practice? 
Authors: Many thanks for this important comment. Indeed the added costs and radiation 
exposure of hybrid imaging are a concern, and do not justify any unrestricted use of the 
techniques. The present manuscript is too limited to identify any subpopulation that may benefit 
from hybrid imaging, and we are unable to address issues of prognostic impact and cost-
efficiency. However, in our personal opinion hybrid imaging may be judiciously used in selected 
patients (e.g. patients with prior CTCA documenting intermediate stenoses or multivessel 
disease as part of a sequential imaging approach). With regard to radiation exposure, previous 
studies suggest that the use of modern equipment and dose-optimization protocols (e.g. 
prospective ECG-triggering for CTCA, stress-only for SPECT) may consistently reduce the 
radiation burden of hybrid imaging, favouring its clinical application on a larger scale. We have 
added this information in the limitations section on page 14 of the revised manuscript.  
 
4. 
Reviewer: Over which time period were the patients included? 
Authors: Patients were enrolled between March 2009 and June 2012. We have added this to the 
methods section on page 4-5 of the revised manuscript. 
 
5.  
Reviewer: Almost 2/3 of the patients were dropped somewhere during the protocol. I most likely 
overlooked it, but could you identify why so many patients were dropped?  
Author: Many thanks for the opportunity to clarify this issue: Figure 1 shows in detail the drop-
outs and specific reasons for it. The majority of drop-outs were not specifically related to the 
hybrid substudy. Per EVINCI protocol, all patients included in the EVINCI trial had to undergo CT 
coronary angiography plus at least one functional imaging test (either stress echo, stress wall 
motion MRI, SPECT of PET). For the hybrid imaging substudy, only patients could be included 
who had myocardial perfusions imaging by SPECT or PET performed, in addition to a CT scan. 
Accordingly, patients submitted to wall motion imaging modalities were not included in the 
analysis, because their format precludes formation of 3D hybrid datasets with CTCA, which  
accounts for the large number of excluded EVINCI patients (n=404). The remaining 41 drop-outs 
were „true drop-outs“ due to either lack of core lab analysis data or inability to generate a hybrid 
data sets due to software incompatibility or incomplete or corrupted datasets. We have now 
clarified this in the revised methods section on page 5.  
 
 
Reviewer #2:  
 
1.  
Reviewer: The paper is well written, methods and results clearly explained. I would skip the 
examples since these are already known from literature. 
Authors: Many thanks for these kind comments. According to this reviewer’s suggestion we have 
skipped figure 6, but decided to keep figure 3 to have at least one practical example in the 
manuscript. We believe that having a practical example in the manuscript will make the topic 
easier to comprehend and demonstrate the clinical relevance of the findings better, particularly 
for readers who are not experienced with such complex imaging protocols. 
 
2.  
Reviewer: Methods: It is amazing that in a major multicenter trial dropout rate was as high as 
mentioned in this study. From the initial 697 patients finally only 252 could be included in this 
study (with different reasons, some also technical). This induces a first major weakness of the 
study: are the conclusions of the study still relevant for the group of patients with low to 
intermediate risk of CAD or only for a very selected subgroup?  
Authors: Many thanks for this important comment. Figure 1 shows in detail the drop-outs and 
specific reasons for it. The majority of drop-outs were not specifically related to the hybrid 
substudy. Per EVINCI protocol, all patients included in the EVINCI trial had to undergo CT 
coronary angiography plus at least one functional imaging test (either stress echo, stress wall 
motion MRI, SPECT of PET). For the hybrid imaging substudy, only patients could be included 
who had myocardial perfusions imaging by SPECT or PET performed, in addition to a CT scan. 
Accordingly, patients submitted to wall motion imaging modalities were not included in the 
analysis, because their format precludes formation of 3D hybrid datasets with CTCA, which  
accounts for the large number of excluded EVINCI patients (n=404). The remaining 41 drop-outs 
were „true drop-outs“ due to either lack of core lab analysis data or inability to generate a hybrid 
data set due to software incompatibility or incomplete or corrupted datasets. Additionally, table 
1 shows that our study population did not differ appreciably from the entire EVINCI cohort with 
regard to the baseline characteristics (age, gender, risk factors, symptomatology) (e.g. our 
pretest probability was 59% compared to 65% in the entire EVINCI population). We have now 
clarified this issue in the Methods section on page 5 and added a paragraph in the Results 
section on page 8 and in the Limitations section on page 13 of the revised manuscript. 
Furthermore, we are giving a modified table 1 in the supplementary appendix (Supplementary 
table A, see below) showing no significant differences between our study population compared 
to the entire EVINCI population as published in the main manuscript (Neglia et al. Circ 
Cardiovasc Imaging. 2015 Mar;8(3). pii: e002179. doi: 10.1161/CIRCIMAGING.114.002179.) 
 
 
Supplementary Table A. Patients’ baseline characteristics 
Parameter EVINCI Hybrid 
Substudy Population                    
(n=252) 
Overall EVINCI Study 
Population             
(475)* 
Demographics, n (%)   
    Age, years  (mean±SD) 61±9 60±9 
    Male gender 161 (64) 291 (61) 
Clinical characteristics, n (%)   
    Typical angina 62 (25) 121 (25) 
    Atypical angina 148 (59) 288 (61) 
    Non-anginal chest pain 42 (17) 66 (14) 
    Pre-test probability of CAD [median (IQR)] 69 (28) 65 (42) 
    Left ventricular ejection fraction >50% 238 (94) 451 (95) 
Cardiovascular risk factors, n (%)   
    Family history of CAD 75 (30) 160 (34) 
    Diabetes mellitus 68 (27) 115 (24) 
    Hypercholesterolemia 161 (64) 267 (56) 
    Hypertension 155 (62) 290 (61) 
    Smoking 60 (24) 120 (25) 
    Obesity 72 (29) 112 (24) 
Invasive coronary angiography data, n (%)   
    Normal coronaries or non-obstructive CAD 158 (63) 335 (70) 
    Single-vessel disease 60 (23) 99 (21) 
    Multi-vessel disease 34 (14) 41 (9) 
Data is given in absolute numbers and percentages (%), unless otherwise stated; CAD denotes 
coronary artery disease 
All comparisons were between both groups were not significant (by Mann Whitney-U test or χ2 
test where appropriate).   
* as published in Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, et al. 
Detection of significant coronary artery disease by noninvasive anatomical and functional 
imaging. Circ Cardiovasc Imaging 2015;8. pii:e002179. Doi:11.1161/CIRCIMAGING.114.002179 
 
 
 
3.  
Reviewer: Methods: The penetration rate of FFR was extremely low in this study (23%) and on 
top of this 34% of the patients with intermediate lesions were not interrogated by FFR. The first 
article referring to the multimodality imaging technique used in this article dates from 2007. 
FAME I was published in January 2010. The results of the complete study EVINCI was only 
published very recently 2015. Data collection was concluded in june 2012: 2.5 years of inclusion 
into EVINCI occurred in an era were FAME proved already the value of FFR. This is a very 
important limitation of this study. The argument of the known gap between EBM and everyday 
clinical practice is an argument in everyday clinical practice but not in a research study as 
EVINCI. 
Authors: We are thankful to this reviewer for bringing up this topic, and fully agree with him that 
the low FFR penetration is a limitation of the study. One reason for this low penetration, is that 
the EVINCI protocol considered a coronary stenosis >70% already hemodynamic significant 
(without evidence of ischemia by FFR). FFR, however, was mandated in stenoses of 30-70%. In 
june 2010, (i.e. 14 months after enrolment of the first patient in the EVINCI study), the FAME 
trialists published, that at least 20% of stenoses with 70-90% stenosis severity were not 
hemodynamically significant by FFR. These findings clearly conflicted with the definition of 
obstructive CAD by the EVINCI protocol, however, the protocol was not amended. Finally, the 
lack of FFR use in one third of intermediate lesions clearly represents a protocol violation. This 
may have financial reasons, as FFR is not reimbursed in all European countries. This is now 
discussed on page 13 in the limitations section of the revised manuscript highlighting that the 
low FFR penetration is a clear limitation of this study.  
 
4.  
Reviewer: Methods: These methodological shortcomings have an important impact on the 
interpretation of the results and on the conclusions. 
Authors: We are not sure to which limitation the reviewer refers in this particular sentence. 
However, we believe that the two main limitations were the high „drop-out rate“ and the low 
penetration of FFR. We have addressed this two limitations in the comments above and have 
added some paragraphs in the limitations section to highlight the importance of these two 
limitations.  
 
5. 
Reviewer: Results: False negative hybrid studies are still an important problem: 41 were false 
negative and probably most of them were really missed ischaemia regions by MPI since from the 
17 FFR measured lesions 13/17 were indeed positive: the mentioned 32% are somewhat 
misleading since this implicates that from the 41 false negatives 77% had indeed lesions 
creating ischaemia although missed by MPI. On the false positive cases, nothing can be 
concluded since FFR was not performed in these patients. 
Authors: Many thanks for this important comment. Indeed, the high false negative rate observed 
in this trial was a concern. However, as shown in figure 4, the false negative rate varies 
considerably based on the definition of what is considered a pathological hybrid study, i.e. 
whether mismatched findings are considered as positives or not. This adds flexibility and at the 
same time also complexity to the definition of coronary artery disease which is no longer a 
binary „Yes/No“ disease but considers the entire anatomofunctional spectrum of disease. 
Indeed, it is possible that in some of the false negative findings, MPI may have failed to detect 
ischemia as evidenced by the positive FFR value. However, this finding is not very suprising 
given the number of reports documenting rather poor agreement between perfusion imaging 
techniques and FFR (e.g. Melikian N, et al. JACC Cardiovasc Interv 2010;3:307-14). Myocardial 
perfusion imaging integrates micro- and macrovascular effects on myocardial blood flow while 
FFR only interrogates a single coronary artery segment (i.e. a small snap-shot of the entire 
coronary vasculature). Furthermore, the cut-off of 0.80 may overestimate the functional 
significance of coronary lesions based on the first comparative studies with non-invasive 
imaging which determined an ideal cut-off of 0.72-0.75 (Pijls NH, et al. N Engl J Med. 1996 Jun 
27;334(26):1703-8.) This may explain partly some of the false negative findings, since a 
significant number (37%) of FFR-positive lesions had „borderline“ significance. We have added 
this data on page 9 of the results section and the supplementary table A and have expanded the 
discussion on this issue on page 12 of the revised discussion section.  
 
6.  
Reviewer: Discussion: The authors claim a high feasibility of the technique. Given the extreme 
high dropout authors cannot claim this. 
Authors: Drop-outs for technical reasons affecting the feasibility of imaging occurred only in 7% 
(see table 1). We would argue that this documents reasonable feasiblility and have changed 
accordingly the term to: “... highlighting the robustness of the technique”  on page 11 of the 
revised discussion section.  
 
7.  
Reviewer: Discussion: In a matched positive hybrid finding 70% were revascularized and the 
authors claim that this is extremely high. I am puzzled with this conclusion: all of these patients 
had an invasive intervention, angio, and had a matched lesion, why was reperfusion not 100%? 
In a matched negative hybrid finding authors claim that invasive evaluation can be safely spared. 
Strange again if 10% of these patients were revascularized! 
Authors: Since the decision for revascularization was left entirely to the judgement of the 
treating physician, i.e. in this case the interventional cardiologist performing the invasive study 
we can only speculate on the answer for for this question: Possible reasons for deferring any 
revascularization procedure may be: small ischemia, technical difficulty (calcified tortuous 
verssels, chronic occlusions), poor target vessel quality, high surgical risk, patient refusal, severe 
comorbidities and others. Potential reasons for performing a revascularization procedure in the 
group of negative hybrid patients could be visual overestimation of stenosis severity, and 
medicolegal considerations. Nevertheless, the reported frequencies for revascularization 
procedures are well in line with those of previously published reports (Pazhenkottil et al. Eur 
Heart J. 2011 Nov;32(22):2824-9; Schaap J et al. Heart. 2013 Feb;99(3):188-94).  
  
8.  
Reviewer: Discussion: In the absence of CAD on CTCA, MPI was + in 39/252 patients and 26% of 
these patients were revascularized! In an era where CTCA is considered as a technique with an 
extremely high negative predictive value this is a rather poor result. 
Authors: Thank you for this important comment. Indeed, CTCA has demonstrated a very high 
negative predictive value in several trials where the gold standard was invasive coronary 
angiography only (without FFR). The fact that we used a more comprehensive 
anatomofunctional gold standard (ICA+FFR) may explain to some extent the lower sensitivity. 
Moreover, the sensitivity of CTCA by core lab analysis in the main EVINCI trial was lower than by 
individual-center analysis (Neglia D, et al. Circ Cardiovasc Imaging 2015;8. pii:e002179). As a 
result, some lesions may have been underestimated accounting for the small number of 
revasculariztions in this group. We have added this information to the discussions section on 
page 12 of the revised manuscript and have added a supplementary figure (Suppl figure 1) with 
the accuracy analysis performed with individual centre-based data (as opposed to core lab data). 
 
10.  
Reviewer: Discussion: As always in diagnostic imaging, adding another technique on top of 
another one results in a dilemma: if you define a positive hybrid exam as a positive CTCA or 
positive MPI, you increase sensitivity at the expense of a reduction in specificity. On the contrary 
if you consider only real positive hybrid imaging as a positive CTCA and a positive MPI, you 
increase specificity but with a dramatic decline in sensitivity. The overall results are in my 
opinion not that spectacular and nothing (or almost nothing) is said about cost-efficiency neither 
on radiation hazard. The only reason why the community would accept a supplementary load on 
cost and radiation would be the fact that a new diagnostic strategy resulted in better patient 
outcome and by this often also a better cost-effective result. These elements are lacking in this 
study. 
Authors: We are very thankful for this important comment and fully agree with this reviewer: 
The assessment of accuracy when two imaging modalities are added becomes immediately more 
complex based on how mismatched findings are considered in the analysis. The main objective 
of the present study was to highlight the complementary role of anatomofunctional modalities 
and their synergistic value over standalone techniques for identifying functionally significant 
coronary lesions (and thereby guide revascularization decisions). The accuracy analysis is only a 
secondary objective and the authors are very aware of the limitations pointed out by this 
reviewer. Unfortunately, the design of the study and the lack of follow-up data precludes to 
assess impact on patient management and cost-efectiveness. Accordingly, we have added the 
limitations with regards to radiation exposure and the need for further studies assessing cost-
effectiveness in the limitations section on page 13 and 14 of the revised manuscript 
 
 
Reviewer #3:  
 
1.  
Reviewer: This is a substudy of the EVINCI trial reporting on 252 patients with stable angina and 
an intermediate pre-test probability for the existence of significant epicardial coronary stenoses. 
Hybrid imaging consisting of either SPECT or PET perfusion imaging plus CT coronary 
angiography was performed in all patients. The result of this extensive and radiation intensive 
diagnostic work up was that 1. 25% of segments were reclassified from their standard coronary 
distribution to another territory and 2. hybrid imaging was able to exclude relevant CAD in 41% 
of patients and confirm relevant CAD in 24% of patients. With respect to the first result one 
wonders about the practical consequences of this finding because patients with regional 
ischaemia based on the findings of SPECT or PET would undergo invasive coronary angiography 
according to current guidelines and also have their coronary perfusion beds reassigned. The 
second result is rather disappointing because it leaves 35% of patients out a definite diagnosis 
with respect to the presence of haemodynamically relevant epicardial stenoses. 
Authors:  We are very thankful to this reviewer for his/her important comments. The reviewer 
has accurately summarized the main findings of the study and rightfully points out concerns 
about the clinical impact of the findings. We are grateful for the opportunity to reply on his 
comments: 1. We respectfully disagree with this reviewer that every patient with myocardial 
ischemia will undergo immediately invasive coronary angiography. In fact, the recently 
published SPARC trial (J Am Coll Cardiol. 2012 Jan 31;59(5):462-74) showed that more than 
80% with mildly anormal and more than 50% of patients with moderately to severely abnormal 
SPECT and PET results are not referred for cardiac catheterization (i.e. conflicting with 
recommendations from current guidelines). This underutilisation of coronary angiography and 
revascularization may be improved through the use of hybrid imaging (Pazhenkottil et al. Eur 
Heart J. 2011 Nov;32(22):2824-9; Schaap J et al. Heart. 2013 Feb;99(3):188-94). Correct 
allocation of myocardial perfusion defects to their tributaries may for example downstage 
suspected 3-VD to 2-VD (as shown in figure 3) for which medical treatment may be justified 
rather than CABG or the opposite, and thereby improve downstream ressource utilisation. 2. The 
fact that 35% of patients in our study had mismatched findings on hybrid imaging and therefore, 
as this reviewer points out, „no clear diagnosis“, may be disturbing but to some degree 
represents the reality of CAD diagnosis. With our manuscript we emphasize that we should 
move away from a binary „yes/no“ paradigm of coronary artery disease, to embrace the entire 
spectrum of coronary disease which includes not only obstructive lesions of the epicardial 
coronary arteries but also non-obstructive disease, diffuse disease, and microvascular 
dysfunction. Hybrid imaging allows to interrogate this entire spectrum yielding a number of 
mismatched findings for which further management decisions are more complex and will need 
further integration of invasive findings and more clinical information.  Finally, the added 
radiation dose from hybrid imaging procedures is an important concern and presently a 
deterrant for the unrestricted use of hybrid imaging. However, the use of modern equipment 
and dose-optimization protocols (e.g. prospective ECG-triggering for CTCA, stress-only for 
SPECT) may consistently reduce the radiation burden of hybrid imaging, favouring its clinical 
application on a larger scale. We have accordingly highlighted the high radiation burden as an 
important limitation of the study in the limitations section on page 14 of the revised manuscript.   
 
2.  
Rewiewer: A certain weakness of the paper is that not all patients had as prespecified FFR 
performed in vessels with stenoses with an angiographic degree of obstruction between 30 and 
70%. In addition, as correctly pointed out by the authors in the discussion, FFR should also be 
performed according to the FAME study in stenoses of 70 to 90% angiographic severity.  
Authors: We are thankful to this reviewer for bringing up this topic, and fully agree with him that 
the low FFR penetration is a limitation of the study. As pointed out by this reviewer, the EVINCI 
protocol considered a coronary stenosis >70% already hemodynamically significant (without 
evidence of ischemia by FFR). FFR, however, was mandated in stenoses of 30-70%. In june 2010, 
(i.e. 14 months after enrolment of the first patient in the EVINCI study), the FAME trialists 
published, that at least 20% of stenoses with 70-90% stenosis severity were not 
hemodynamically significant by FFR. This findings clearly conflicted with the definition of 
obstructive CAD by the EVINCI protocol, however, the protocol was not amended. This is now 
discussed on page 13 in the limitations section of the revised manuscript, highlighting that the 
low FFR penetration is a clear limitation of this study.  
 
3.  
Reviewer: Abstract: In the conclusions the authors talk about "patients at low-intermediate risk 
of CAD". However, according to the US guidelines (Fihn et al. JACC 2012) intermediate pre-test 
probability is defined as a probability between 20 and 70% whereas the European guidelines 
define the intermediate range as existing between 15 and 85%. The NICE guidelines extend the 
intermediate range to 10 to 90%. Thus, the choice of 20 to 90% as in this paper is unusual. 
Definitely, these patients were not in the low-intermediate risk group but in the intermediate 
risk group. 
Authors: We thank the reviewer for having pointed out this aspect of the previous version of the 
manuscript. As correctly remarked, the definition of intermediate probability of CAD varies quite 
significnatly accrording to the specific guidelines or scientific statements that are considered.  In 
the EVINCI study the specific range of probabilities was defined according to the best scientific 
evidence available at the time of the conception of the study. Specifically, the 2006 ESC 
guidelines for the management of CAD were chosen (Fox K, Garcia MA, Ardissino D, Buszman P, 
Camici PG, Crea F, et al. Eur Heart J doi:10.1093/eurheartj/ehl001). In that document a pre-test 
probability of CAD >90% was considered "elevated", while a probability <10% was defined 
"very low". In line with that evidence, a range of probabilities of 20-to-90% ollowed to 
reasonably exclude patients at low risk of CAD, selecting only the intermediate risk group. We 
have changed accordingly the sentence in the abstract from „low-to-intermediate“ to 
„intermediate“ risk and added a new reference (ref. 11) in the reference list. 
 
4. 
Reviewer: Page 6, myocardial perfusion scintigraphy: How was the presence of myocardial scar 
interpreted for diagnostic purposes in this context? 
Authors: In our primary analysis, a scar was considered as a pathological MPS finding (i.e. the 
presence of a scar defined as a summed rest score ≥2 was considered as positivity for MPS). We 
are now stating this clearly on page 6 of the revised manuscript.  The rationale for using 
myocardial scar as a criterion for positivity was that in the majority of cases the presence of a 
scar in a CAD-naive patient with signs and symptoms of CAD would probably prompt further 
diagnostic testing. Nonetheless, to address this reviewer’s comment, we performed a separate 
analysis where only ischemia was accepted as a criterion for MPS positivity. We did not find any 
major differences in accuracy comparing ischemia only to ischemia+scar as the positivity 
criterion for SPECT or PET (see below). We are now stating this on page 13 of the revised 
manuscript, however, we chose not to inlude an additional figure in the manuscript in order not 
to overload the manuscript with accuracy analyses (see also comment #8 by the second 
reviewer). 
 
 
Accuracy in detecting significant CAD using the presence of reversible ischemia as the only 
positivity criteria for MPI and Hybrid imaging. 
 
Per vessel analysis          Per patient analysis 
 
 
 
5. 
Reviewer: Page 12, end of paragraph 1: the authors point out that of 19 coronary lesions with a 
pathological FFR only 4 had a matched perfusion defect. This clearly suggests that the currently 
used cut-off for a pathologic FFR measurement of 0.80 is too liberal resulting in a substantial 
overestimation of clinically relevant ischaemia caused by the stenosis in question. Indeed, the 
original cut-off proposed by the inventors of FFR was 0.75. Yet, the authors suggest that it would 
be clinically justified based on their results to have symptomatic patients with pathologic CT 
coronary angiography yet normal myocardial perfusion scans undergo invasive FFR 
measurements. 
Authors: We totally agree with this reviewer, that the FFR cut-off at 0.80 may be too liberal and 
overestimate the severity of lesions in some instances. Indeed, 37% of lesions without 
myocardial ischemia on MPS but positive FFR had values in the range of 0.75 to 0.80, which is a 
grey zone for which clinical recommendations are not yet totally clear. We have added this 
information on page 12 of the discussions section in the revised manuscript. The DEFER study 
(now with 15 year follow-up: Zimmermann et al. Eur Heart J. 2015 Dec 1;36(45):3182-8), for 
example, suggested that it is safe to defer revascularization in patients with single vessel disease 
if FFR values were higher than 0.75. On the other hand, the FAME II trial (De Bruyne et al. N Engl 
J Med. 2014 Sep 25;371(13):1208-17) showed that in multivessel disease patients 
revascularization of all lesions with an FFR value lower than 0.80 improved outcomes. As a 
result, some interventional cardiologists consider the 0.80 cut-off valid in main branches (e.g. 
left main, proximal LAD), while they are more liberal in side branches.  Nevertheless, in some of 
these patients, it may be wise to take the final decision about revascularization after all 
information from noninvasive and invasive imaging has been integrated with regard to extent 
and severity of disease, justifying a complete noninvasive/invasive assessment. 
 
6. 
Reviewer: Page 13: After reading this study one wonders whether hybrid imaging is really worth 
the added expenses and radiation. 
Authors: We agree that concerns of added costs and radiation exposure exist. However, at least 
with regard to radiation exposure many new developments in the field of CT and SPECT exist, 
which have already substantially lowered radiation exposure compared to the techniques used 
in the original EVINCI trial. We have therefore added a paragraph dealing with the issue of 
radiation reduction on page 14 of the revised manuscript.  
 
 
Reviewer #4:  
 
1. 
Reviewer: The EVINCI study, first presented in June 2012 and with primary results published in 
Circ Imaging (2015;8: pii: e002179), aimed to study combined anatomic and functional imaging 
for the assessment of coronary artery disease in patients with intermediate likelihood.  The 
primary publication found that coronary CT angiography (CCTA) had the highest diagnostic 
accuracy of the modalities considered, in comparison to a reference standard of quantitative 
coronary angiography and fractional flow reserve (in the small minority of patients in which it 
was performed).  The present manuscript focuses on hybrid imaging with 3D image fusion of 
myocardial perfusion scintigraphy (MPS) and CCTA images, in the 252 EVINCI patients who 
underwent CCTA, MPS, and invasive angiography.  The authors' major findings here were: 1) 
hybrid (fused) imaging reassigned 25% of visually-classified abnormal myocardial segments, in 
18% of patients, from one coronary vascular distribution to another; 2) fusion imaging could be 
performed in 93% of patients, with high inter-rater agreement.  Reclassification occurred in 
49% of myocardial segments visually classified as belonging to the left circumflex (36% to LAD 
and 13% to RCA), in 32% classified to the right coronary (19% to LAD and 13% to LCx), and in 
only 2% of segments classified to the left anterior descending.  Correlating these changes with 
CCTA findings, the reclassification moved the perfusion defect to the distribution of a coronary 
artery with a stenosis on CTA in 16 patients ("matched finding"), and away from a stenosis in 3 
of the 252 patients. 
Fused imaging generates pretty pictures but requires two costly tests, which for most patients is 
not justified (excepting those with equivocal first tests).  It requires specialized software which 
is not necessary since each study can be interpreted independently and the results combined 
without the images being combined.  For example if MPS shows an inferior perfusion defect and 
CCTA shows a stenosis only of the circumflex, it is clear that that defect reflects ischemia from 
the circumflex, not from the RCA, even without fancy fused pictures.  And in any event, if the 
patient is symptomatic despite optimal medical therapy and has either one of these tests 
performed demonstrating significant coronary disease, then invasive angiography is probably 
this right next test to perform.  If on invasive angiography the inferior defect seen on MPS is 
found to be associated with only a circumflex stenosis then it is clear that the circumflex should 
be intervened upon, not the right coronary.  The additional performance of pre-cath CCTA would 
not significantly impact clinical decision-making in this patient - they would wind up with a 
circumflex stent in any event.  An analogous argument can be made were CCTA the initial test - 
then MPS would not impact clinical decision-making.  Thus I take issue with the authors' 
conclusion that hybrid imaging impacts clinical decision-making in 18% of patients.  Pre-
catheterization segmental reclassification is not equivalent to an impact on clinical decision-
making, and the authors do not provide any strong data regarding the latter. 
Authors: Many thanks to this reviewer for his/her insightful comments. We fully agree with this 
reviewer that limitations for hybrid imaging exist, and that its indiscriminate should not be 
recommended. The incremental costs and radiation exposure of the technique are limitations. 
We have thus added an additional paragraph on page 14 of the revised manuscrip highlighting 
this limitation. Furthermore, the study was not designed to obtain follow-up information, 
therefore it is beyond the scope and the design of the manscript to assess the impact of hybrid 
imaging on downstream ressource ustilisatio, patient management and outcomes. We have 
further added this as a limitation on page 13 of the revised manuscript.  
We agree that in the majority of patients, the fact that hybrid imaging may reassign coronary 
perfusion territories will have limited clinical impact. We rather see the added clinical value in 
patients with multivessel disease where revascularization decisions are more complex. This is 
best demonstrated by the example given in figure 3, where reassigning ischemic segments from 
the LCX territory to the RCA territory was able to downstage suspected 3-vessel disease (where 
CABG is the preferred revasc technique) to 2-vessel disease (where PCI or even medical 
treatment may be considered). Another potential scenario may be reassigning of a perfusion 
defect from a territory subtended by a difficult chronic total occlusion (where PCI would most 
likely fail and CABG would be required) to a territory subtended by a easy type A stenosis. 
However, we fully agree with this reviewer that such complex coronary cases are rare, and that 
the majority of patients are appropriately managed without hybrid imaging.  
 
2.  
Reviewer: The authors do not seem to use the term "intention-to-diagnose" correctly.  For 
example they state "According to an intention-to-diagnose strategy, any non-diagnostic segment 
was considered abnormal."  My understanding of "intention-to-diagnose" is that it is analogous 
to "intention-to-treat", whereby patients are classified as to the group corresponding to the 
diagnostic test which was intended to be performed for the patient, irrespective of what test(s) 
were or weren't actually performed.  As such "intention-to-diagnose" has nothing to do with 
classification of non-diagnostic segments.  You can simply state that a prior a decision was made 
to classify non-diagnostic segments as abnormal. 
Authors: Many thanks for this comment. We have changed this accordingly on page 6 of the 
revised manuscript.  
 
3.  
Reviewer: The authors acknowledge that incomplete use of FFR may account for some false-
negative and false-positive hybrid findings.  Why was a uniform reference standard not applied? 
Authors: We are thankful to this reviewer for bringing up this topic, and fully agree with him that 
the low FFR penetration is a limitation of the study. Nonetheless, it was a declared aim of the 
EVINCI trialists to avoid a purely anatomical gold standard of invasive coronary angiography 
which would intrinsically favour angiographical tests like CT coronary angiography, and thereby 
(by using a comprehensive anatomofunctional gold standard consisting of ICA plus FFR) 
overcome the limitations of innumerable previous diagnostic studies. However, one reason for 
the low FFR penetration is that the EVINCI protocol considered a coronary stenosis >70% 
already hemodynamic significant (without evidence of ischemia by FFR). FFR, however, was 
mandated in stenoses of 30-70%. In june 2010, (i.e. 14 months after enrolment of the first 
patient in the EVINCI study), the FAME trialists published, that at least 20% of stenoses with 70-
90% stenosis severity were not hemodynamically significant by FFR. This findings clearly 
conflicted with the definition of obstructive CAD by the EVINCI protocol, however, the protocol 
was not amended. Finally, the lack of FFR use in one third of intermediate lesions clearly 
represents a protocol violation. This may have financial reasons, as FFR is not reimbursed in all 
European countries. We have added a senstence in the limitations section on page 13 
highlighting that the low FFR penetration is a clear limitation of this study.  
 
 
Reviewer #5:  
 
1.      
Reviewer: Out of 697 patients, only 252 = 36% are included in this hybrid imaging substudy due 
to various reasons. How were these patients different from the 445 patients that were not 
included? How did this bias affect the results of the study? 
Authors: We are very thankful to this reviewer for his insighful comments. The high „drop-out“ 
rate is indeed a concern and a limitation of the study. Table 1 shows that our study population 
did not differ appreciably from the entire EVINCI cohort with regard to the baseline 
characteristics (age, gender, risk factors, symptomatology) (e.g. our pretest probability was 59% 
compared to 65% in the entire EVINCI population). We have now clarified this in the Methods 
section on page 5 and added a paragraph on this in the Results section on page 8 and in the 
Limitations section on page 13 of the revised manuscript. Furthermore, we are giving a modified 
table 1 in the supplementary appendix (Supplementary table A, see below) showing no 
significant differences between our study population compared to the entire EVINCI population 
as published in the main manuscript (Neglia et al. Circ Cardiovasc Imaging. 2015 Mar;8(3). pii: 
e002179. doi: 10.1161/CIRCIMAGING.114.002179.) 
 
 
Supplementary Table A. Patients’ baseline characteristics 
Parameter EVINCI Hybrid 
Substudy Population                    
(n=252) 
Overall EVINCI Study 
Population             
(475)* 
Demographics, n (%)   
    Age, years  (mean±SD) 61±9 60±9 
    Male gender 161 (64) 291 (61) 
Clinical characteristics, n (%)   
    Typical angina 62 (25) 121 (25) 
    Atypical angina 148 (59) 288 (61) 
    Non-anginal chest pain 42 (17) 66 (14) 
    Pre-test probability of CAD [median (IQR)] 69 (28) 65 (42) 
    Left ventricular ejection fraction >50% 238 (94) 451 (95) 
Cardiovascular risk factors, n (%)   
    Family history of CAD 75 (30) 160 (34) 
    Diabetes mellitus 68 (27) 115 (24) 
    Hypercholesterolemia 161 (64) 267 (56) 
    Hypertension 155 (62) 290 (61) 
    Smoking 60 (24) 120 (25) 
    Obesity 72 (29) 112 (24) 
Invasive coronary angiography data, n (%)   
    Normal coronaries or non-obstructive CAD 158 (63) 335 (70) 
    Single-vessel disease 60 (23) 99 (21) 
    Multi-vessel disease 34 (14) 41 (9) 
Data is given in absolute numbers and percentages (%), unless otherwise stated; CAD denotes 
coronary artery disease 
All comparisons were between both groups were not significant (by Mann Whitney-U test or χ2 
test where appropriate).   
* as published in Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, et al. 
Detection of significant coronary artery disease by noninvasive anatomical and functional 
imaging. Circ Cardiovasc Imaging 2015;8. pii:e002179. Doi:11.1161/CIRCIMAGING.114.002179 
 
 
2.   
Reviewer: Similarly, only 23% underwent FFR and a distal 34% of the intermediate lesions had 
FFR. While this was a pragmatic, comparative effectiveness study, this is a very low percent of 
FFR use for a study where QCA and FFR form the reference standard and in the background of 
FAME and FAME-2, not reflective of current use of FFR either. The rate may reflect the rate of 
clinical use of FFR in the participating countries at the time of the study, but this makes for a 
poor reference standard from a study perspective. 
Authors: We fully agree with this reviewer that the low FFR penetration is a limitation of the 
study. One reason for the low FFR penetration, is that the EVINCI protocol considered a 
coronary stenosis >70% already hemodynamic significant (without evidence of ischemia by 
FFR). FFR, however, was mandated in stenoses of 30-70%. In june 2010, (i.e. 14 months after 
enrolment of the first patient in the EVINCI study), the FAME trialists published, that at least 
20% of stenoses with 70-90% stenosis severity were not hemodynamically significant by FFR. 
This findings clearly conflicted with the definition of obstructive CAD by the EVINCI protocol, 
however, the protocol was not amended. Finally, the lack of FFR use in one third of intermediate 
lesions clearly represents a protocol violation. This may have financial reasons, as FFR is not 
reimbursed in all European countries. We have added a senstence in the limitations section on 
page 13 highlighting that the low FFR penetration is a clear limitation of this study.  
 
 
3.      
Reviewer: The average dose of radiation for SPECT/CTCA, which was done in 71% of the 
included patients was quite high at 18.5 mSv, which is very concerning given the risk of 
secondary cancer. In the era of cardiac MR perfusion imaging, which involves no radiation, and 
CT-FFR, which involves no extra radiation over CTCA, this is a major issue and not very well 
discussed in the manuscript. According to the AHA Scientific Statement on "Approaches to 
Enhancing Radiation Safety in Cardiovascular Imaging" (Fazel et al. Circulation 2014;130), 
"when a cardiac imaging study is appropriate, if a comparable test that does not use ionizing 
radiation (e.g., echocardiography or cardiac magnetic resonance imaging) is able to provide the 
clinical information needed with comparable accuracy, cost, and convenience but lower overall 
risk (taking into consideration other potential risks, such as those related to use of gadolinium 
contrast agents or anesthesia), then it may be the preferred approach". I would argue that 
hybrid imaging may improve over CTCA or SPECT individually, but the increased radiation 
presents a significant risk, which could be avoided with use of a comparable test that does not 
use ionizing radiation (e.g., echocardiography or cardiac magnetic resonance imaging).  
Authors: Many thanks for this important comment. Indeed the radiation exposure for hybrid 
studies is a clear safety concern and limits the indiscriminate use of the technique. However, 
many now developments in the field of CT and SPECT exist, which have already substantially 
lowered radiation exposure compared to the techniques used in the original EVINCI trial. We 
have therefore added a paragraph dealing with the issue of radiation reduction on page 14 of the 
revised manuscript. With regard to alternative techniques (CMR perfusion or stress echo),  
technical issues prevent their use for 3D hybrid imaging. Both, CMR perfusion and stress 
echocardiography obtain two-dimensional datasets of myocardial perfusion which are very 
challenging to warp onto three-dimensional CT coronary angiograms. And even if this was 
possible the low interplane resolution of CMR (only three short axis slices of the entire left 
ventricle are obtained) is insufficient for hybrid imaging. Novel faster CMR perfusion sequences 
will soon become available which will allow to obtain a full 3D dataset of LV myocardial 
perfusion more suitable for fusion with CT coronary angiography (Manka R. Eur Heart J. 2011 
Nov;32(21):2625), but until these sequences are widely implemented, nuclear/CT fusion 
remains the most practical and robust hybrid technique and the only one that has been tested in 
diagnostic studies.  
 
4.  
Reviewer: Overall, this study is a good proof-of-concept study that hybrid imaging may be better 
than CTCA or nuclear imaging alone, but the difficulty in conducting per-protocol imaging 
studies even in this multi-center research study, and the high radiation used for hybrid imaging 
suggest that hybrid imaging is unlikely to have a significant clinical impact in the current era. 
Authors: Many thanks for this comment. We fully agree with this reviewer, that limitations exist 
however, we believe that with further technological developments (including the increased 
availability of hybrid devices, the efforts in lowering radiation from CT and radionclide imaging) 
hybrid imaging may play an ever increasing role in the future. Furthermore, studies like this one 
may set an example for applying hybrid imaging to other areas on cardiology (e.g. detection of 
infective endocarditis with PET/CT, use of hybrid imaging to determine responders of CRT, 
assessment of plaque structure and biology with hybid imaging, real-life hybrid imaging in 
structural heart disease interventions, etc.).  
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Abstract 
 
Aims Hybrid imaging provides a non-invasive assessment of coronary anatomy and myocardial perfusion. 
We sought to evaluate the added clinical value of hybrid imaging in a multi-centre multi-vendor setting.  
Methods and results Fourteen centres enrolled 252 patients with stable angina and intermediate (20-90%) 
pre-test likelihood of coronary artery disease (CAD) who underwent myocardial perfusion scintigraphy 
(MPS), CT coronary angiography (CTCA), and quantitative coronary angiography (QCA) with fractional 
flow reserve (FFR). Hybrid MPS/CTCA images were obtained by 3D image fusion. Blinded core-lab 
analyses were performed for CTCA, MPS, QCA and hybrid datasets. Hemodynamically significant CAD 
was ruled-in non-invasively in the presence of a matched finding (myocardial perfusion defect co-localized 
with stenosed coronary artery) and ruled-out with normal findings (both CTCA and MPS normal).  
Overall prevalence of significant CAD on QCA (>70% stenosis or 30-70% with FFR≤0.80) was 37%. Of 
1004 pathological myocardial segments on MPS, 246 (25%) were reclassified from their standard coronary 
distribution to another territory by hybrid imaging. In this respect, in 45/252 (18%) patients, hybrid imaging 
reassigned an entire perfusion defect to another coronary territory, changing the final diagnosis in 42% of 
the cases. Hybrid imaging allowed non-invasive CAD rule-out in 41%, and rule-in in 24% of patients, with 
a negative and positive predictive value of 88% and 87%, respectively.  
Conclusions In patients at intermediate risk of CAD, hybrid imaging allows non-invasive co-localization of 
myocardial perfusion defects and subtending coronary arteries, impacting clinical decision-making in 
almost one every five subjects. 
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Abstract 
 
Aims Hybrid imaging provides a non-invasive assessment of coronary anatomy and myocardial perfusion. 
We sought to evaluate the added clinical value of hybrid imaging in a multi-centre multi-vendor setting.  
Methods and results Fourteen centres enrolled 252 patients with stable angina and intermediate (20-90%) 
pre-test likelihood of coronary artery disease (CAD) who underwent myocardial perfusion scintigraphy 
(MPS), CT coronary angiography (CTCA), and quantitative coronary angiography (QCA) with fractional 
flow reserve (FFR). Hybrid MPS/CTCA images were obtained by 3D image fusion. Blinded core-lab 
analyses were performed for CTCA, MPS, QCA and hybrid datasets. Hemodynamically significant CAD 
was ruled-in non-invasively in the presence of a matched finding (myocardial perfusion defect co-localized 
with stenosed coronary artery) and ruled-out with normal findings (both CTCA and MPS normal).  
Overall prevalence of significant CAD on QCA (>70% stenosis or 30-70% with FFR≤0.80) was 37%. Of 
1004 pathological myocardial segments on MPS, 246 (25%) were reclassified from their standard coronary 
distribution to another territory by hybrid imaging. In this respect, in 45/252 (18%) patients, hybrid imaging 
reassigned an entire perfusion defect to another coronary territory, changing the final diagnosis in 42% of 
the cases. Hybrid imaging allowed non-invasive CAD rule-out in 41%, and rule-in in 24% of patients, with 
a negative and positive predictive value of 88% and 87%, respectively.  
Conclusions In patients at intermediate risk of CAD, hybrid imaging allows non-invasive co-localization of 
myocardial perfusion defects and subtending coronary arteries, impacting clinical decision-making in 
almost one every five subjects. 
 
 
Keywords: hybrid imaging; myocardial perfusion scintigraphy; CT coronary angiography; coronary artery 
disease  
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Introduction 
 
The risk of patients with stable coronary artery disease (CAD) varies considerably based on the extent of 
anatomical involvement and of myocardial ischemia.1 Unfortunately, there is disagreement between the 
angiographic severity of CAD and myocardial perfusion abnormalities.2,3 Thus, current guidelines 
recommend a comprehensive anatomo-functional assessment to decide on the most appropriate treatment, 
with patients at low-risk treated conservatively, while high-risk patients are generally referred for more 
aggressive therapies.1 Specifically, revascularization strategies should be guided by the presence of 
hemodynamically significant coronary stenosis, while non-significant coronary stenoses may be treated 
conservatively.4,5 
 Recently, hybrid cardiac imaging has emerged as a non-invasive way of assessing CAD by 
integration of myocardial perfusion images with individual coronary anatomy.6 Small studies have 
suggested superior diagnostic accuracy compared with the separate imaging modalities,7 whereas others 
have reported incremental prognostic value.8 While the technique is finding increasing acceptance in 
clinical practice, questions remain over the clinical role of hybrid imaging. Furthermore, the impact of the 
technique has never been tested in a multi-centre, multi-device, real-world setting. 
 This study sought to assess the clinical role of hybrid cardiac imaging in a multi-centre study using 
different equipment and practice, and to explore its value for the diagnosis of hemodynamically significant 
CAD.   
 
Methods 
 
Study Design.  
The EVINCI (EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of 
Ischemic Heart Disease) study is a “European Commission 7th Framework Program for Research and 
Innovation” sponsored multi-modality imaging project in 14 centres from 9 European countries.9 The 
characteristics of the study population have been already described in detail,9 and are summarized in Table 
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1. Briefly, between March 2009 and June 2012, patients with symptoms suggestive of CAD and 
intermediate pre-test probability (20-90%)10, 11 underwent a study of coronary anatomy by CT coronary 
angiography (CTCA) and at least one coronary functional imaging test by myocardial perfusion 
scintigraphy (MPS) (single-photon emission computed-tomography (SPECT) or positron emission 
tomography (PET) and/or wall motion imaging (stress echocardiography or cardiac magnetic resonance), 
with the recommendation to perform invasive coronary angiography (ICA) with fractional flow reserve 
(FFR) in intermediate lesions. Each patient was followed-up for 30 days and the referral for coronary 
revascularization recorded. Ethical approval was provided by each centre and all subjects gave written 
informed consent.  
 
Image acquisition 
Acquisition protocols were agreed on for each technique based on best available clinical practice. 
Individual core labs were responsible for harmonization and quality control of imaging protocols. Details 
on imaging procedures and protocols can be found in the EVINCI publication.9 All EVINCI subjects in 
whom core-lab analyses of CTCA, MPS and ICA were available were selected for the present hybrid sub-
study (Figure 1). Accordingly, patients submitted to wall motion imaging modalities were not included in 
the analysis, because their format precludes formation of 3D hybrid datasets with CTCA. No further 
exclusion criterion was considered.  
 
Image Fusion  
MPS and CTCA datasets were transferred to a dedicated hybrid core-lab blinded to clinical history and 
imaging findings (Cardiac Imaging, University Hospital Zurich, Switzerland). Image fusion of MPS and 
CTCA datasets was performed on a dedicated workstation (Advantage Workstation 4.4, GE Healthcare) 
using the CardIQ Fusion software package (GE Healthcare) as previously described.12 In case of H215O-
PET images, parametric myocardial blood flow datasets, showing flows on a segmental level, were 
generated based on quantitative analysis performed using a commercially available software, (PMOD 3.6 
software package. PMOD Technologies Ltd., Zurich, Switzerland).  
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Hybrid analysis was performed using an optimized alignment tool, allowing projection of the MPS image 
on the left ventricular epicardial surface obtained from the CTCA, allowing a panoramic view of the 
coronary artery tree projected onto the left ventricular myocardial perfusion territories. In all patients, the 
image fusion procedure (including image generation and reading) was performed by two independent and 
blinded operators. Disagreement with regard to allocation of myocardial perfusion defects was resolved by 
consensus reading.  
 
Image interpretation and definitions 
Image interpretation was performed in dedicated core-labs as follows:   
 
CT coronary angiography 
CTCA was assessed using a modified 16-segment system13 and considered abnormal if at least one 
coronary segment had a diameter stenosis >50%. Significant left main stem stenosis were assigned to both 
left anterior descending (LAD) and left circumflex (LCX) coronary arteries. To limit any selection bias, 
any non-diagnostic segment was considered abnormal. 
 
Myocardial perfusion scintigraphy 
Perfusion in each of 17 segments14 was visually classified as 0=normal, 1=mild reduction, 2=moderate 
reduction, 3=severe reduction or 4=absent perfusion, and the segmental scores were summed for the stress 
(SSS) and rest (SRS) images. 15O-H2O PET data were processed and parametric perfusion images were 
scored similarly. The difference between SSS and SRS was calculated as the summed difference score 
(SDS). On per patient analysis, a reversible perfusion defect (ischemia) was defined as a SDS ≥2, either 
from a score ≥1 in at least two contiguous segments or ≥2 in at least one segment. Myocardial scar was 
defined similarly as a SRS ≥2. Accordingly, MPS studies were considered pathological in the presence of 
significant myocardial ischemia and/or scar.  
For per-vessel analysis, a reversible perfusion defect (ischemia) was defined as a territorial difference score 
≥1, and a scar as a rest score ≥1. Each perfusion defect was assigned to one or more coronary territories 
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according to the standardized myocardial segmentation model14. Similarly to CTCA analysis, any non-
diagnostic segment was considered abnormal. 
 
Invasive coronary angiography 
Coronary angiograms were subdivided using the previously mentioned segmentation model13 and analysed 
using quantitative coronary angiography (QCA). A stenosis was considered hemodynamically significant if 
causing a >50% diameter reduction in the left main stem or >70% elsewhere, or between 30% and 70% 
with a FFR ≤0.80.  
 
Hybrid images 
All hybrid MPS/CTCA images were analysed by consensus of two independent readers with regard to the 
presence of matched, mismatched or normal findings. A matched finding was defined as a perfusion defect 
in a territory subtended by a stenotic coronary. All other combinations of pathological findings were 
classified as mismatched. In the absence of pathological findings on both CTCA and MPS hybrid images 
were considered normal. Finally, all pathological MPS segments were assigned to the pertinent vascular 
territory by spatial co-registration according to individual coronary anatomy by both operators to determine 
inter-observer agreement and repeatability of hybrid-based co-registration. 
 
Statistical analysis 
Statistical analysis was performed using the SPSS software. Continuous variables were expressed as 
mean±SD, and categorical variables as percentages. Numerical values were compared using the Mann-
Whitney U test or Student’s t test, and categorical values using the χ2 test. Inter-observer agreement was 
assessed using Cohen’s kappa statistic. Sensitivity, specificity, and accuracy were calculated for each 
imaging method (MPS, CTCA, and hybrid imaging) on a per-vessel and per-patient basis. The McNemar 
test was performed to compare the accuracy of the different imaging methods against QCA±FFR. A value 
of P<0.05 was considered significant.  
 
Results 
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Patient population 
A total of 252 patients underwent CTCA, MPS and ICA, and were included in the analysis (Figure 1). The 
characteristics of the study populations are shown in Table 1. Compared with the overall EVINCI 
population,9 there were no significant differences in baseline characteristics except for a slightly higher 
CAD prevalence in our patient population (37% vs 30%, P=0.05) (Supplementary table A).  
Interestingly, as in the case of the main EVINCI population, also in the present study traditional 
criteria for calculating pre-test probability11 overestimated the prevalence of hemodynamically significant 
CAD, which was 37% at QCA±FFR. FFR was performed in 58/252 patients (23% of all patients and 66% 
of patients with intermediate coronary stenoses), and was abnormal (≤0.80) in 19 patients.  
 
Imaging results: MPS and CTCA 
One-hundred and eighty (71%) patients were submitted to SPECT while 72 (29%) underwent PET (Table 
2). Overall, 104 (41%) patients presented myocardial perfusion abnormalities in one (8%), two (41%) or 
three (51%) vascular territories. At core-lab analysis, MPS images were judged of non-diagnostic quality 
(having at least 1 non-diagnostic segment) in 11 patients. 
On CTCA, 111 (44%) patients presented significant CAD in one (48/111, 43%), two (41/111, 
37%) or three (22/111, 20%) vessels (Table 2) with no significant difference between patients submitted to 
SPECT or PET. At core-lab analysis, CT images were judged of non-diagnostic quality (having at least 1 
non-diagnostic segment) in 8 patients. 
 
Hybrid imaging: feasibility and repeatability 
In 18/270 (7%) patients originally submitted to CTCA and MPS, hybrid imaging could not be 
accomplished due to corruption of original data-sets (8 patients) or software incompatibility (10 patients).  
Inter-rater agreement of hybrid-based co-registration was good (k=0.75 95% CI 0.70-0.80) with 
both observers agreeing in the classification of 92% of all pathological myocardial segments. 
 
Hybrid Imaging: segment reclassification 
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A total of 4284 myocardial segments were analyzed, of which 1004 (23%) were pathological. According to 
the standard myocardial segmentation model, 397 (39%), 269 (27%), and 338 (34%) abnormal segments 
were allocated to the LAD, LCX and right coronary artery (RCA) vascular territory, respectively. After 
image fusion, 246 (25%) of the 1004 abnormal myocardial segments were reclassified from their standard 
coronary distribution to another territory (Table 3). Segment reclassification was highest for the standard 
LCX (49%) and RCA (32%) segments, while it was very low for standard LAD segments (2%; P <0.001 vs 
both LCX and RCA). Figure 2 shows the proportion of pathological segments reassigned by hybrid 
imaging.  
In 45/252 (18%) patients hybrid imaging reassigned an entire perfusion defect to another coronary 
territory, changing the final diagnosis in 19 cases (from a mismatched to a matched finding in 16 patients, 
and the opposite in 3). Interestingly, in 16 (84%) of those patients the myocardial perfusion abnormality 
was correctly assigned to a territory subtended by a hemodynamically significant stenosis at QCA±FFR. 
The role of hybrid analysis in the anatomo-functional characterization of patients and in identifying 
significant CAD is exemplified in Figure 3. 
 
“Rule-in/rule-out” clinical algorithm 
The diagnostic accuracy of hybrid imaging and of stand-alone imaging modalities in detecting significant 
CAD (QCA±FFR) is reported in Figure 4 
Specifically, a matched finding at hybrid imaging was found in 61 patients (24%) while103 
patients (41%) had normal hybrid findings. Of the remaining 88 patients with mismatched abnormal 
findings (35%), 45 presented a positive CTCA in the absence of perfusion abnormalities at MPS, while 39 
showed a pathological MPS despite the absence of obstructive CAD at CTCA. Revascularization rates were 
70% for matched hybrid images, 36% for mismatched findings, and 10% for normal findings (P<0.001).  
(Figure 5). 
 Interestingly, among the 41 “false negative” hybrid studies (either normal or mismatched findings 
in the presence of significant CAD at QCA), the majority (80%) showed negative MPSs, despite a stenotic 
vessels on CTCA in 64% of the cases. FFR was performed in 17/41 patients and was positive in 13 (76%). 
(Suppl. Table B). On the other hand, the “false-positive” hybrid studies were almost exclusively associated 
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with the presence of intermediate coronary lesions (>30% and ≤70%) on QCA mainly in the absence of an 
invasive assessment of the hemodynamic relevance of stenoses by FFR (Suppl. Table C).  
 
Radiation burden of the non-invasive imaging protocol  
Average radiation doses in the study population were 7.9 mSv (range 0.6-24 mSv) for CTCA, 10.4 mSv 
(range 3.2-17.5 mSv) for SPECT, and 1.8 mSv (range 1.7-3.5 mSv) for PET. The average radiation dose of 
hybrid imaging was 9.4 mSv (range 5.2-21 mSv) for PET/CTCA and 18.5 mSv (range 6-31 mSv) for 
SPECT/CTCA (P<0.001). 
 
Discussion 
 
 The EVINCI hybrid sub-study is one of the largest studies to assess the clinical value of non-
invasive hybrid imaging in stable CAD. Several methodological advantages, including the use of dedicated 
blinded core-lab image analysis, the multicenter and multivendor design, and the use of an accepted 
invasive gold standard (QCA±FFR), distinguish it from previously published reports and provide greater 
uniformity and generalizability of its results. The main findings of the study are: (i) large variability of 
coronary anatomy leading to systematic errors of standardized myocardial segmentation in predicting 
culprit coronary vessels. (ii) Hybrid imaging (by 3D co-registration of CTCA and MPS) is feasible and 
reproducible. (iii) A hybrid anatomo-functional protocol allows non-invasive “rule-in and rule-out” of 
hemodynamically significant CAD.  
Standardized myocardial segmentation models are widely used to assign myocardial territories to 
subtending coronary arteries.14 However, coronary anatomy is highly variable, which may frequently lead 
to mistaken identification of culprit vessels by standard models. In this respect, it has been previously 
suggested that hybrid imaging may help in the individual co-localization of myocardial perfusion 
abnormalities and subtending coronary arteries.15–18   
We identified systematic deviation from the standardized assignment of myocardial segments in 
25% of pathological segments, localized almost exclusively in the standard LCX and RCA territories (i.e. 
the lateral and inferior myocardial wall). This turned out to be clinically significant in almost every fifth 
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patient, in whom the entire perfusion defect was reassigned to another coronary artery, changing the final 
diagnosis in almost half of them. This result might be of particular relevance in patients considered for 
revascularization, where only hemodynamically significant lesion deserve treatment. 5,19 
 Previous reports have shown the feasibility and reproducibility of 3D fusion of anatomical 
(CTCA) and functional (MPS) imaging.12 In this study, hybrid analysis was successfully performed in 93% 
of the EVINCI patients originally submitted to MPS and CTCA with good inter-observer repeatability, 
highlighting the robustness of the technique. In fact, technical image fusion failure occurred in only 7% of 
patients mainly in the case of early generation SPECT devices with incomplete or corrupted datasets or 
software incompatibility. 
Given the heterogeneity of hybrid results (combining various anatomo-functional patterns) we 
considered that a binary diagnostic approach disregards the complexity of CAD. Conversely, a “rule-
in/rule-out” hybrid-based approach appears more clinically meaningful, since matched positive findings 
allow rule-in of CAD and matched normal findings CAD rule-out (Figure 5). Accordingly, although in the 
EVINCI study the clinical management of patients, including the decision for coronary revascularization, 
was entirely left to the judgment of the local clinician, possibly introducing a bias in the analysis of the 
data, a matched positive hybrid finding was still associated with a high early revascularization rate (70%). 
On the other hand, in patients with a completely negative hybrid report the revascularization rate was 
extremely low (≈10%), making ICA theoretically superfluous. It should be emphasized that the majority of 
false negatives hybrid studies was due to negative MPS downstream a stenotic coronary vessel at CTCA 
which was confirmed by a >70% lumen diameter reduction at QCA (considered as hemodynamically 
significant). After the FAME study,2 published almost at the end of the EVINCI study, coronary stenoses 
between 70% and 90% should be also submitted to FFR since a considerable proportion of these lesions 
have a normal FFR. On the other hand, the false positive hybrid imaging studies were essentially associated 
with the presence of intermediate coronary lesions (>30% and ≤70%) that did not undergo an invasive  
evaluation of their hemodynamic relevance through FFR and, thus, considered as not significant. It is 
conceivable that, if FFR would have been more extensively performed, the number of “false negative” and 
“false positives” results could have been considerably reduced. Interestingly, a consistent proportion of 
those patients were still submitted to coronary revascularization despite the absence of an objective proof of 
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myocardial ischemia (either by MPS or through FFR) (Suppl. Table B and Suppl. Table C), further 
highlighting the existing gap between evidence-based patient management1, 3, 5, 19 and everyday clinical 
conduct.20 
Patients with mismatched findings (positive MPS/negative CTCA or negative MPS/positive CTCA) 
represent a heterogeneous group. In the absence of coronary stenoses on CTCA, myocardial perfusion 
defects may represent either artefacts or microvascular/endothelial dysfunction. Accordingly, in this group 
CAD prevalence and revascularization rates were low (Figure 5). CTCA has a very high negative 
predictive value as demonstrated by a vast number of studies comparing it to the angiographical gold 
standard of ICA.21 The fact that we used a more comprehensive anatomofunctional gold standard 
(ICA+FFR) may explain to some extent the low sensitivity. Moreover, the sensitivity of CTCA by core lab 
analysis in the main EVINCI trial was lower than by individual-center analysis.9 As a result, some lesions 
may have been underestimated accounting for the small number of revascularizations in this group. 
Conversely, patients with significant coronary stenoses on CTCA but absence of perfusion defects 
had a substantial CAD prevalence and revascularization rate (40 and 42%, respectively). This finding has 
several explanations. On one hand, the gold standard used in the present study was mainly anatomical 
(QCA), favouring agreement with CTCA rather than MPS. On the other hand, as already shown22 the cut-
off chosen for FFR (≤0.80)5,19 may overestimate the hemodynamic significance of CAD compared with 
non-invasive ischemia testing. In line with this evidence, among the 19 patients with a pathological FFR 
evidenced in this study, only 21% had a matched finding on hybrid imaging. Interestingly, only 12/19 
(63%) of those lesions presented a FFR ≤0.75, as a more stringent cut-off for positivity3. However, the 
incomplete FFR penetration observed in the present study, mainly due to protocol violations, does not 
allow defining whether the use of a lower cut-off value of FFR would have better correlated with hybrid 
findings. 
Such a “rule-in/rule-out” protocol is supported by follow-up data, indicating low event rates in 
patients with normal hybrid findings, high event rates for pathological matched findings, and intermediate 
event rates with mismatched findings.8 Moreover, in selected cases, our integrated protocol may overcome 
the limitations of the more simplistic binary (i.e. either functional or anatomic) approach usually applied to 
CAD diagnostics, as recently reported.23  
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Limitations  
Like the overall EVINCI population, our study had a significant drop-out rate, as not every patient 
underwent all protocol-specified imaging studies. Additionally, data corruption and incomplete datasets 
accounted for further drop-outs. Accordingly, 252 of the 697 patients originally enrolled in the EVINCI 
study were included in the present sub-study. However, those represented all the EVINCI patients that 
underwent MPS, CTCA and ICA and in whom, thus, hybrid analysis could be practically performed. In 
fact, only a marginal portion of those patients (7%) was excluded because of technical reasons, confirming 
the overall robustness of 3D image fusion. Moreover, since the demographical, clinical and angiographic 
characteristics of the present patients were almost superimposable to those of the main EVINCI 
population,9 the presence of a significant selection bias can be excluded (Supplementary table A). Second, 
no long-term follow-up data was obtained precluding any analysis on the impact of hybrid imaging on 
downstream patient management and outcomes. Third, FFR rate was only 23%, and 34% of patients with 
intermediate lesions were not interrogated with FFR. Incomplete FFR penetration due to frequent protocol 
violations highlights the sub-optimal FFR use across Europe and may have been responsible for some of 
the “false negative” hybrid findings and prevents any conclusive analysis on the “false positive” studies 
(Suppl. Table B and C). In our study, the respective sensitivities of CTCA and MPS were lower than 
anticipated from small single-centre studies (particularly for CTCA: 78%). This may be explained by 
selecting higher risk patients who had additional MPS performed, as well as by the inclusion of patients 
with intermediate stenosis (30-70%) without invasive functional evaluation, and by the exclusive use of 
independent core-lab data for the present analysis. In fact, the accuracies of standalone imaging modalities 
reported were almost superimposable to those of the overall EVINCI study when only core-lab data were 
considered.9 Notably, on centre-based analysis the diagnostic accuracy of the different non-invasive 
imaging modalities was generally improved compared to the core-lab data. Nevertheless, even when only 
individual centre-data were considered, hybrid imaging maintained significantly elevated specificity and 
overall diagnostic accuracy, both at per-patient and vessel-based analysis (Suppl. Figure 1). 
Moreover, in the accuracy analyses, MPS was considered pathological in the presence of ischemia 
and/or scar. Interestingly, the presence of a matched hybrid finding showed comparable sensitivity, 
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specificity and accuracy if myocardial ischemia (and not scar) was considered as the only positivity criteria 
(50%, 96%, and 79%, respectively).  
Finally, the added radiation exposure from hybrid protocols must be also considered. In the 
present study, average radiation doses varied considerably, depending on the imaging technique (PET vs 
SPECT) and on the acquisition protocol employed. Specifically, the theoretical risk related to the radiation 
exposure of a SPECT/CTCA hybrid protocol may appear rather high, particularly if compared to 
PET/CTCA imaging or other non-invasive imaging modalities.24 However, previous results suggest that the 
use of modern equipment and dose-optimization protocols (e.g. prospective ECG-triggering for CTCA, 
stress-only for SPECT) may consistently reduce the radiation burden of hybrid imaging,25 favouring its 
clinical application on a larger scale. Nevertheless, further long-term comparative studies are probably 
needed to conclusively define the cost-efficiency and quantitate the added radiation hazard that may be 
related to hybrid imaging, and to definitively assess its possible prognostic impact. 
 
  
Conclusions 
Hybrid imaging allows more reliable co-localization of myocardial perfusion defects with subtending 
coronary arteries than standardized myocardial segmentation models accounting for variations in individual 
coronary anatomy. In two-thirds of patients at intermediate pre-test probability of CAD, hybrid imaging 
may offer a non-invasive “rule-in or rule-out” of patients with hemodynamically significant CAD.  
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Figure Legends 
 
Figure 1 Patient flow chart. Coronary CT angiography (CTCA); invasive coronary angiography (ICA); 
fractional flow reserve (FFR); myocardial perfusion imaging (MPS) 
 
Figure 2 (A) Standardized myocardial segmentation model used in this study with number codes for each 
segment (see Table 3) (13). (B) Reassignment rates by hybrid imaging for the 1004 pathological segments 
(the intensity of colours in each segment indicates the frequency of reassignment of that segment when 
pathological). (C) Pie chart indicating proportion of reassignment and reassignment fate for pathological 
segments in each standard coronary territory. Shades of red indicate standard LAD, of green standard LCX, 
of blue standard RCA territories. Standard LCX segments were most often reassigned to LAD (36%), while 
standard RCA segments where equally distributed between LAD and LCX.  
 
Figure 3 A 55-year old gentleman with atypical chest pain. (A) SPECT shows a reversible perfusion defect 
inferiorly with lateral extension, and in addition, there is a separate reversible perfusion defect involving 
the the apical region and the midventricular anteroseptal wall. (B) The perfusion polar maps show the 
SPECT core lab interpretation (white=normal, yellow=mildly reduced, orange=moderately reduced, and 
red=severely reduced radiotracer uptake) with pathological segments assigned to all three coronary 
territories. (C) CTCA reveals two 70-90% mid LAD stenoses, a 50% proximal LCX stenosis, and a 
probable occlusion of the mid RCA (arrows). (D) On hybrid imaging, the entire inferolateral perfusion 
defect is reassigned to the RCA, effectively changing the diagnosis from 3-vessel to 2-vessel disease. (E) 
Imaging findings were confirmed on QCA showing two high-grade lesions in the mid LAD, diffuse non-
significant disease in the LCX, and a chronic total occlusion of the mid RCA.  
 
Figure 4 Accuracy analysis of stand-alone and hybrid protocols for the diagnosis of significant CAD (by 
QCA±FFR) on per-vessel (A) and per-patient (B) analysis. On a per-vessel basis, when positivity was 
defined by the presence of at least one positive test (either matched or mismatched findings), hybrid 
imaging had higher sensitivity than single modalities (P<0.001 vs MPS and CTCA), at the price of lower 
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specificity (P<0.001 vs both MPS and CTCA) and accuracy (P<0.001 vs both MPS and CTCA). When only 
matched findings were considered positive, hybrid imaging increased accuracy (P<0.001 vs both MPS and 
CTCA) driven by higher specificity (P<0.001 vs both MPS and CTCA) but with lower sensitivity (P<0.001 
vs MPS and CTCA).  
 
Figure 5 Hybrid-based “rule in/rule out” clinical protocol. 
 
Supplementary Figure 1 Accuracy analysis of stand-alone and hybrid protocols for the diagnosis of 
significant CAD (by QCA±FFR) on per-vessel (A) and per-patient (B) analysis using individual centres 
data. On a per-vessel basis, when positivity was defined by the presence of at least one positive test (either 
matched or mismatched findings), hybrid imaging had higher sensitivity than single modalities (P<0.001 vs 
MPS and CTCA), at the price of lower specificity and accuracy. When only matched findings were 
considered positive, hybrid imaging increased accuracy driven by higher specificity (P<0.001 vs both MPS 
and CTCA) but with lower sensitivity.  
 
 
 
 Table 1. Patients’ baseline characteristics 
Parameter Overall Population         
(n=252) 
Demographics, n (%)  
    Age, years  (mean±SD) 61±9 
    Male gender 161 (64) 
Clinical characteristics, n (%)  
    Typical angina 62 (25) 
    Atypical angina 148 (59) 
    Non-anginal chest pain 42 (17) 
    Pre-test probability of CAD * 59±23 
    Left ventricular ejection fraction 59±9 
Cardiovascular risk factors, n (%)  
    Family history of CAD 75 (30) 
    Diabetes mellitus 68 (27) 
    Hypercholesterolemia 161 (64) 
    Hypertension 155 (62) 
    Smoking 60 (24) 
    Obesity 72 (29) 
Invasive coronary angiography data, n (%)  
    Normal coronaries or non-obstructive CAD 158 (63) 
    Single-vessel disease 60 (23) 
    Multi-vessel disease 34 (14) 
Myocardial perfusion imaging, n (%)  
    Single-photon emission computed tomography 180 (71) 
 99mTc-Sestamibi 103 (57) 
 99mTc-Tetrofosmin 77 (43) 
    Positron emission tomography 72 (29) 
 15O-Water 63 (88) 
 13N-Ammonia 8 (11) 
 82Rubidium 1 (1) 
Data is given in absolute numbers and percentages (%), unless otherwise stated; CAD 
denotes coronary artery disease 
* pre-test probability was calculated based on Ref. 10 
 
Table 1
 Table 2. Noninvasive imaging data 
Parameter Overall 
Population         
(n=252) 
SPECT  
 
(n=180) 
PET         
 
(n=72) 
P 
value 
Myocardial perfusion imaging data     
    Normal perfusion 148 (59) 111 (62) 37 (58) 0.175 
    Scar 41 (16) 35 (19) 6 (8) 0.037 
    Inducible ischemia 88 (35) 54 (30) 34 (47) 0.013 
Computed tomography data    0.599 
    One-vessel disease 48 (19) 38 (21) 10 (14)  
    Two-vessel disease 41 (16) 29 (16) 12 (17)  
    Three-vessel disease 22 (9) 15 (8) 7 (10)  
Hybrid imaging    0.054 
    Hybrid Match 61 (24) 39 (22) 22 (31)  
    Hybrid Mismatch 88 (35) 68 (38) 20 (28)  
        MPS positive and CT negative 39 (15) 26 (14) 13 (18)  
        MPS negative and CT positive 49 (19) 42 (23) 7 (10)  
    Normal Hybrid 103 (41) 73 (41) 30 (42)  
Data is given as numbers and percentages, n (%); MPS denotes myocardial perfusion imaging 
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Table 3. Hybrid-based reclassification of myocardial perfusion abnormalities  
Standard coronary 
distribution 
Myocardial Segments     
(17 segments  
LV model)* 
Perfusion 
abnormality, n 
Abnormal segment 
reclassified,         
 n (%) 
To LAD   
 n (%) 
To LCX           
n (%) 
To RCA      
n (%) 
 
 
 
             
      LAD 
Segment 1 50 0 (0) - 0 (0) 0 (0)  
Segment 2 51 1 (2) - 0 (0) 1 (100)  
Segment 7 56 0 (0) - 0 (0) 0 (0)  
Segment 8 48 0 (0) - 0 (0) 0 (0)  
Segment 13 62 0 (0) - 0 (0) 0 (0)  
Segment 14 51 1 (2) - 0 (0) 1 (100)  
Segment 17 79 6 (8) - 2 (33) 4 (67)  
 
 
       LCX 
Segment 5 72 25 (35) 0 (0) - 25 (100)  
Segment 6 43 20 (47) 19 (95)  - 1 (5)  
Segment 11 58 20 (34) 17 (85) - 3 (15)  
Segment 12 44 31 (70) 30 (97)  - 1 (3)  
Segment 16 52 35 (67) 30 (86) - 5 (14)  
 
 
       RCA 
Segment 3 55 13 (24) 10 (77) 3 (23) -  
Segment 4 82 15 (18) 0 (0) 15 (100) -  
Segment 9 52 15 (29) 12 (80) 3 (20) -  
Segment 10 76 15 (20) 0 (0) 15 (100) -  
Segment 15 73 49 (67) 42 (86) 7 (14) -  
LV denotes left ventricle; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery 
* For exact location of perfusion segment within the LV see figure 2A. 
Table 3
697 patients enrolled in the 
EVINCI Study
341 patients with ICA +/- FFR
78 Drop outs
278 Protocol violations:
•54 did not undergo both CCTA 
and imaging stress-test
•224 did not undergo ICA
293 patients with both MPI 
and CCTA
48 did not undergo MPI
270 patients with blinded 
core-lab data
23 not evaluated by the 
pertinent core-labs
Final population of the 
"Hybrid substudy": 
252 patients
• 10 software incompatibility
• 8 incomplete or corrupted datasets
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Accuracy in detecting significant CAD 
(QCA±FFR)
B. Per-patient analysis
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Figure 4
“Hybrid-analysis”
n=252
Regional MPI 
and CTCA
normal findings 
n=103 (41%)
Regional MPI and 
CTCA mismatched 
abnormal findings
n=88 (35%)
Regional MPI and 
CTCA matched
abnormal findings 
n=61 (24%)
Rule-out 
Significant CAD 
Sens: 87% 
NPV: 88%
Revasc. Rate=10%
CTCA-/MPI+ (n=39)
Significant CAD=21%
Revasc. Rate=26%
Rule-in 
Significant CAD 
Spec: 95% 
PPV: 87%
Revasc. Rate=70%
CTCA+/MPI- (n=45)
Significant CAD=40%
Revasc. Rate=42%
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